Search Results
Article Topics
Your search for all items matches 19823 pages
Showing 1 - 50Artificial Intelligence to Guide Management of Pancreatic Cysts
In a proof-of-concept study, an international scientific team has shown that a laboratory test using artificial intelligence tools has the potential to more accurately sort out which people with pancreatic cysts will eventually develop pancreatic cancers. Their findings were published by Springer...
Association Between ADT for Prostate Cancer and Diagnosis of Alzheimer Disease or Dementia in Older Patients
In a report published by Jayadevappa et al in JAMA Network Open, researchers found that among older patients with prostate cancer, treatment with androgen-deprivation therapy (ADT) was associated with a subsequent diagnosis of Alzheimer disease or dementia over a follow-up period of at least 10...
AACR Immune Cell Therapies: Early Study Results Suggest Activity of Multiantigen T-Cell Therapy in Patients With Pancreatic Cancer
Findings from a small phase I study investigating a nonengineered, multiantigen-specific T-cell therapy for the treatment of pancreatic cancer has found that the therapy had clinical activity and was safe and well tolerated. The early results suggest that the immune cell therapy may provide a...
Stratification Tool to Predict VTE in Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
New research published by Li et al in JNCCN–Journal of the National Comprehensive Cancer Network has identified a way to help clinicians caring for patients with multiple myeloma to predict blood clots in order to take preventive action. The researchers established a set of risk factors to...
Upgrading of Nonmelanoma Skin Cancers at the Time of Mohs Surgery
Nonmelanoma skin cancers may display an aggressive histologic subtype that is not diagnosed on initial biopsy. In a prospective, cross-sectional study reported by Kyllo et al in the Journal of the American Academy of Dermatology, researchers determined that a significant portion of nomelanoma...
Poorer Outcomes for Patients With Lung Cancer Undergoing Radiotherapy During Disaster-Level Hurricanes
Patients who experienced a disaster-level hurricance during radiotherapy for lung cancer had worse overall survival than those who completed treatment in normal circumstances, with longer disaster declarations associated with increasingly worse survival. These findings come from a...
Does the Association Between Diet and Colonic Mucosa–Associated Microbiota Affect Cancer Risk?
A report published by Liu et al in The American Journal of Clinical Nutrition found an association between diet quality and microbiome composition in human colonic mucosa. The researchers found that a high-quality diet is linked to more potentially beneficial bacteria, whereas a...
Maintenance Panitumumab vs Panitumumab/Fluorouracil/Leucovorin in RAS Wild-Type Metastatic Colorectal Cancer
In an Italian phase II trial reported in JAMA Oncology, Pietrantonio et al found that maintenance panitumumab alone was inferior in terms of progression-free survival (PFS) compared to maintenance panitumumab plus fluorouracil/leucovorin in RAS wild-type metastatic colorectal cancer. Study Details ...
Ramucirumab Plus Pembrolizumab in Previously Treated Advanced Gastroesophageal Cancer, NSCLC, and Urothelial Carcinoma
Results from a phase IB trial expansion stage reported in The Lancet Oncology by Herbst et al showed the combination of ramucirumab plus pembrolizumab had manageable toxicity and antitumor activity in previously treated advanced gastroesophageal cancer, non–small cell lung cancer (NSCLC), and ...
Role of IL-6/JAK1 Pathway in the Treatment of Hepatocellular Carcinoma
A recent study published by Chan et al in the Journal of Clinical Investigation found a cellular pathway associated with cancer may be beneficial in reducing side effects and extending duration of immunotherapy in some patients with hepatocellular carcinoma. IL-6/JAK1 Pathway Researchers...
Fragility Analysis of Phase III Trials Supporting FDA Approval of Anticancer Drugs
In an analysis reported in The Lancet Oncology, Del Paggio and Tannock found that many phase III trials supporting U.S. Food and Drug Administration (FDA) approval of anticancer drugs have a low fragility index—a measure of how many people in a study would have had to have a different outcome ...
Rise in Early-Onset Colorectal Cancer Not Fully Aligned With Screening Trends
A new study finds that trends in colonoscopy rates did not fully align with recent increases in colorectal cancer incidence in younger adults. The findings were published by Fedewa et al in the Journal of Medical Screening. Colorectal cancer incidence rates are declining in adults older than...
Incidence of Olaratumab Infusion-Related Reactions
In a study reported in the Journal of Oncology Practice, Van Tine et al found that infusion-related reactions occurred in 14.4% of patients receiving olaratumab in clinical trials, with grade ≥ 3 events occurring in 2.3%. (Olaratumab was withdrawn from the global market on April 25, 2019, based...
Does Size of Surgical Excision Margins for Thick Localized Cutaneous Melanoma Affect Survival Outcomes?
In a nearly 20-year follow-up of a Scandinavian trial reported in The Lancet, Utjés et al found no difference in survival outcomes with 2-cm vs 4-cm surgical excision margins for primary localized cutaneous melanoma with a thickness > 2 mm. The previous report from the trial showed no...
Biliary Microbiome Altered in Patients Undergoing Surgery After Neoadjuvant Therapy for Pancreatic Cancer
The biliary microbiome was altered in patients who received neoadjuvant therapy prior to undergoing surgery for pancreatic cancer, according to a study published by Goel et al in HPB. Additionally, more bacteria in patients who underwent surgery after neoadjuvant therapy were resistant to...
Role of Regulatory T Cells in Predicting Breast Cancer Relapse
Blood and intratumoral regulatory T-cell activity may one day provide a method for predicting breast cancer relapse, according to findings published by Wang et al in Nature Immunology. “This is the first success linking a solid tumor with blood biomarkers—an indicator of whether a...
Receipt of Radioactive Iodine Treatment for Differentiated Thyroid Cancer and Perception of Patient Choice
In a study reported in the Journal of Clinical Oncology, Wallner et al found that many patients with differentiated thyroid cancer reported feeling they had no choice in receipt of radioactive iodine treatment. As stated by the investigators, “For many patients with differentiated thyroid...
Long-Term Health Outcomes After Lymphome Malin de Burkitt Chemotherapy for Pediatric Mature B-Cell Non-Hodgkin Lymphoma
In a study reported in the Journal of Clinical Oncology, Ehrhardt et al found that long-term health outcomes were comparable in patients receiving contemporary Lymphome Malin de Burkitt (LMB) vs non-LMB chemotherapy regimens for pediatric mature B-cell non-Hodgkin lymphoma, except for adverse...
Neoadjuvant Radiotherapy vs Surgery Alone for Resectable Hepatocellular Carcinoma With Tumor Thrombus
In a Chinese study reported in the Journal of Clinical Oncology, Wei et al found that neoadjuvant three-dimensional conformal radiotherapy improved outcomes vs hepatectomy alone in patients with resectable hepatocellular carcinoma with portal vein tumor thrombus. Study Details In the multicenter...
Biden Cancer Initiative Suspends All Operations
Today, the Biden Cancer Initiative announced it would suspend all operations. The Initiative, which launched on June 26, 2017, is an independent nonprofit organization that was built on the goals of the White House Cancer Moonshot program created by President Barack Obama and led by Vice President ...
Addition of Preoperative NBTXR3 to Radiotherapy in Locally Advanced Soft-Tissue Sarcoma
In the phase II/III Act.In.Sarc trial reported in The Lancet Oncology, Bonvalot et al found that preoperative addition of the radioenhancer hafnium oxide nanoparticle NBTXR3 to radiotherapy may improve outcomes in patients with locally advanced soft-tissue sarcoma. The agent acts to increase...
Ivosidenib for Advanced IDH1-Mutated Advanced Cholangiocarcinoma
Ivosidenib, a small-molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), is currently being studied in a phase I clinical trial assessing its efficacy in patients with IDH1-mutated solid tumors. In a report published by Lowery et al in The Lancet Gastroenterology & Hepatology, researchers...
Economic Burden of Cancer in the United States in 2015
There were more than 8.7 million person-years of life lost and $94.4 billion in earnings lost due to cancer among people aged 16 to 84 in the United States in 2015. The calculation comes from a new report published by Islami et al in JAMA Oncology. Cancer is the second-leading cause of death...
Subtypes of Pancreatic Neuroendocrine Tumors and Effect on Disease Recurrence
Researchers have discovered two distinct subtypes of pancreatic neuroendocrine tumors (pNETs) associated with different risks of recurrence following surgical treatment. The finding could yield predictive tests while focusing vigilant follow-up monitoring on patients with pNETs that have a higher...
Anesthesia Exposure and Neurocognitive and Neuroimaging Outcomes in Long-Term Survivors of Childhood ALL
In a study reported in JAMA Oncology, Banerjee et al found that higher cumulative anesthesia exposure and duration of exposure during treatment of childhood acute lymphoblastic leukemia (ALL) may be associated with adverse neurocognitive and abnormal neuroimaging outcomes in long-term survivors....
Is There an Increased Long-Term Risk for Ovarian Cancer After Assisted Reproductive Technology?
Fertility treatment is not associated with an increased long-term risk of ovarian cancer, according to the results of a large-scale multicenter study presented by Spaan et al at the 35th Annual Meeting of the European Society of Human Reproduction and Embryology (Abstract O-183). The findings,...
FDA Pipeline: Designations and Applications Granted in Lymphoma, Small Cell Lung Cancer, Multiple Myeloma, and More
Recently, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to a phospholipid-drug conjugate in diffuse large B-cell lymphoma; granted Orphan Drug designation to an immunotherapy for small cell lung cancer (SCLC); accepted supplemental biologics license applications (sBLAs) ...
Study Identifies Key Biologic Features of Upper Tract Urothelial Carcinoma
A new study published by Robinson et al in Nature Communications aimed to learn more about the biologic characteristics of upper tract urothelial carcinoma to help develop more targeted therapies. “We discovered the defining biologic characteristics of [upper tract urothelial tumors] that...
Intervention to Promote Breast Cancer Surveillance in Childhood Cancer Survivors Who Received Chest Radiotherapy
In the EMPOWER trial, which took place within the larger Childhood Cancer Survivor Study (CCSS) and was reported in the Journal of Clinical Oncology, Oeffinger et al found that an intervention consisting of mailed educational materials followed by telephone-delivered counseling led to an increased...
Substitution of Clofarabine for Anthracycline/Etoposide in Induction Therapy for Pediatric Acute Myeloid Leukemia
In the phase III AML08 trial reported in the Journal of Clinical Oncology, Rubnitz et al found that the use of clofarabine instead of an anthracycline and etoposide in the first course of induction therapy may be a feasible strategy in pediatric patients with acute myeloid leukemia. The trial,...
Friends of Cancer Research Launches Next Phase in Real-World Evidence Initiative
Friends of Cancer Research (Friends) is launching the next phase of its Real-World Evidence (RWE) pilot project after a broad stakeholder meeting in February 2019. At the meeting, the U.S. Food and Drug Administration (FDA) and various data partners expressed interest in...
Cost-Effectiveness of Single-Marker Genetic Testing vs Multigene Panel Sequencing in Advanced NSCLC
The results of an economic modeling study to estimate the cost-effectiveness of multigene panel sequencing as compared to standard-of-care single-gene tests for patients with advanced non–small cell lung cancer (NSCLC) showed that multigene panel sequencing tests are moderately...
KIR-HLA System Gene Loci Imbalance and Biliary Tract Cancer
Patients with biliary tract cancer have an altered genetic architecture in some immune system receptor systems, according to research published by Cornillet et al in Gastroenterology. Research Findings Researchers at Karolinska Institutet investigated the genetic architecture of two large genetic ...
Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events
In a study reported in JAMA Oncology, Simonaggio et al found that rechallenge with an immune checkpoint inhibitor after occurrence of immune-related adverse events was associated with occurrence of an immune-related adverse event in approximately half of patients, with no increase in severity....
Does Centralization of High-Risk Cancer Surgery in Hospital Systems Improve Outcomes?
In a study reported in the Journal of Clinical Oncology, Sheetz et al identified the degree of centralization of high-risk cancer surgeries within hospital systems and found improved short-term outcomes with increased centralization among Medicare patients. Study Details The study involved...
ReDOS: Regorafenib Dose-Escalation Strategy in Refractory Advanced Colorectal Cancer
In the phase II ReDOS trial reported in The Lancet Oncology, Bekaii-Saab et al found that a regorafenib dose-escalation strategy compared favorably with standard dosing in regard to toxicity profile and activity in patients with refractory advanced colorectal cancer. Study...
Combination Therapy With Immunochemotherapy and an Antibody-Drug Conjugate in DLBCL
As reported in The Lancet Oncology, Hervé Tilly, MD, and colleagues found that the combination of polatuzumab vedotin, an antibody-drug conjugate targeting the CD79b component of the B-cell receptor, with immunochemotherapy showed high response rates in the phase II portion of a phase I/II study in ...
Effect of Bortezomib/Dexamethasone Plus Pomalidomide on Progression-Free Survival in Multiple Myeloma Pretreated With Lenalidomide
In the phase III OPTIMISMM trial, reported by Paul G. Richardson, MD, and colleagues in The Lancet Oncology, researchers found that the addition of pomalidomide to bortezomib/dexamethasone improved progression-free survival in relapsed or refractory multiple myeloma previously treated with...
Addition of Antiangiogenic Agent to First-Line Carboplatin/Paclitaxel in Ovarian Cancer
In a phase III trial (TRINOVA-3/ENGOT-ov2/GOG- 3001) reported in The Lancet Oncology, Ignace Vergote, PhD, and colleagues found that addition of the antiangiogenic agent trebananib to carboplatin/ paclitaxel did not improve progression-free survival in first-line treatment of advanced ovarian...
A Pioneering Surgeon Who Opened Doors for Others, LaSalle D. Leffall, Jr, MD, Dies at 89
Lifting himself from the barriers of the segregated South, LaSalle D. Leffall, Jr, MD, would become a nationally regarded oncologic surgeon who opened doors for other in the medical profession. His career was distinguished by “firsts,” such as the first African America President of both the...
Henry T. Lynch, MD, Trailblazer in Hereditary Cancers, Dies at 91
Henry T. Lynch, MD, widely known as “the father of cancer genetics,” had an early life that could have been lifted from the pages of a Louis L’Amour novel. He dropped out of high school and using a falsified birth certificate joined the U.S. Navy at 16 years old, serving as a gunner on a marine...
Chaga Mushroom
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Ting Bao, MD, DABMA, MS, and Jyothirmai Gubili, MS, explore the current...
How Immunologic Dysregulation in the Multiple Myeloma Microenvironment May Affect Response to CAR T-Cell Therapy
Despite an avalanche of novel therapies approved by the U.S. Food and Drug Administration (FDA) over the past decade in the treatment of multiple myeloma, including proteasome inhibitors and immunomodulatory drugs, this blood cancer remains largely incurable, and nearly 13,000 people are expected...
FDA Approves New Trastuzumab Biosimilar
On June 14, the U.S. Food and Drug Administration (FDA) approved trastuzumab-anns (Kanjinti) for all approved indications of the reference product trastuzumab (Herceptin): for the treatment of HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction...
The Bomb
I sit paralyzed at my desk. Everyone else has left the clinic. I can hear the sound of the broom in the hall as the after-hours cleaning begins. No phones ring, no patients hurry to appointments, no chatter lingers in the air. The silence is oppressive, the air is heavy, and the distance from my...
Growing Up in a Medical Family Planted the Seed for a Career in Oncology for Karen Gelmon, MD
Karen Gelmon, MD, was born and reared in Saskatoon, the largest city in the Canadian province of Saskatchewan. It is surrounded by vast prairie and situated along the Trans-Canada Yellowhead Highway and is home to the University of Saskatchewan. “We lived close to the University,” she shared. “My...
Trifluridine/Tipiracil in Recurrent, Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma
In the Clinic provides overviews of novel hematology and oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On February 22, trifluridine/tipiracil...
Endowment Helps George Washington University Cancer Center to Create Position of Dr. Cyrus Katzen Family Director
The George Washington University (GW) Cancer Center has announced the establishment of the Dr. Cyrus Katzen Family Director of the GW Cancer Center, thanks to a gift from GW alumnus and former Board of Trustee member Jay Katzen, MD. The gift will support the ongoing growth and expansion of the GW ...
Queen Elizabeth II Bestows Honor on V. Craig Jordan, OBE, PhD, DSc, FMedSci
On June 7, 2019, Professor V. Craig Jordan, OBE, PhD, DSc, FMedSci, was appointed Companion of the Most Distinguished Order of St. Michael and St. George by Queen Elizabeth II on her 93rd birthday. Each year, the Queen recognizes the achievements of people from across the British Commonwealth. Dr. ...
Willie Underwood III, MD, MSc, MPH, Elected to AMA Board of Trustees
The American Medical Association (AMA) announced the election of Willie Underwood III, MD, MSc, MPH, a urologist based in Buffalo, New York, to its Board of Trustees. A board-certified urologic surgeon specializing in prostate cancer, Dr. Underwood has been an active leader in organized medicine...
